Tin tức & Cập nhật
Xem bài viết Nội tiết
Xem
Canagliflozin holds promise against MAFLD in T2D patients
Patients with type 2 diabetes (T2D) who received canagliflozin benefit from improved liver biochemistry and metabolism, a recent study has shown. In addition, treatment with canagliflozin appears to confer positive effects on liver fibrosis.
Canagliflozin holds promise against MAFLD in T2D patients
27 Oct 2023
High red meat consumption increases risks of CVD and diabetes
Higher consumption of both unprocessed and processed red meat is associated with higher risks of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM), according to a meta-analysis involving >4.4 million people by researchers from the University of Hong Kong (HKU).
High red meat consumption increases risks of CVD and diabetes
27 Oct 2023
Oral health checks integral to diabetes management
A population-based study suggests that the incidence of periodontitis co-occurs with various other diabetes-related complications, underpinning the importance of oral health checks in diabetes management.
Oral health checks integral to diabetes management
24 Oct 2023
Roflumilast serves up weight-loss benefit for patients with psoriasis
In the treatment of patients with psoriasis, the phosphodiesterase (PDE)-4 inhibitor roflumilast has been found to also induce weight loss.
Roflumilast serves up weight-loss benefit for patients with psoriasis
20 Oct 2023
Newly diagnosed T2D linked to earlier CVD events
A new diagnosis of type 2 diabetes (T2D) raises the risk of cardiovascular disease (CVD) development within 10 years in both men and women and across age groups, particularly among younger patients, reveals a recent study.
